Challenges of Manufacturing Bi/Multispecific Modalities

This technical report discusses the challenges associated with the manufacturing of bi- and multispecific antibodies (BsAbs) in the pharmaceutical industry. It outlines the increasing focus on next-generation drug products that enhance targeted delivery and efficacy while reducing development costs. The report details the current market landscape, noting that there are two FDA-approved BsAb products and over 85 in clinical development, with expectations for significant market growth by 2025. It explains the advantages of BsAbs, such as their ability to bind to multiple antigens, which can lead to improved therapeutic outcomes. The report also addresses the complexities involved in the manufacturing processes, including issues related to expression, product quality, and scalability. Various production platforms and technologies are highlighted, emphasizing the need for optimized systems to meet the demands of these advanced therapeutics. The report concludes with a summary of the importance of developing robust manufacturing capabilities to support the growing pipeline of bi/multispecific modalities.